Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Prognostic model for patient survival in primary anorectal mucosal melanoma: stage at presentation determines relevance of histopathologic features.

Nagarajan P, Piao J, Ning J, Noordenbos LE, Curry JL, Torres-Cabala CA, Diwan AH, Ivan D, Aung PP, Ross MI, Royal RE, Wargo JA, Wang WL, Samdani R, Lazar AJ, Rashid A, Davies MA, Prieto VG, Gershenwald JE, Tetzlaff MT.

Mod Pathol. 2019 Aug 5. doi: 10.1038/s41379-019-0340-7. [Epub ahead of print]

PMID:
31383963
2.

Comment on: External Validation of the Simplified Preoperative Assessment for Low-Grade Mucinous Adenocarcinoma of the Appendix.

Dineen SP, Royal RE, Mansfield PF, Fournier KF.

Ann Surg Oncol. 2017 Dec;24(Suppl 3):627. doi: 10.1245/s10434-017-6218-3. Epub 2017 Nov 9. No abstract available.

PMID:
29124485
3.

Stratification of outcomes for mucinous appendiceal adenocarcinoma with peritoneal metastasis by histological grade.

Grotz TE, Royal RE, Mansfield PF, Overman MJ, Mann GN, Robinson KA, Beaty KA, Rafeeq S, Matamoros A, Taggart MW, Fournier KF.

World J Gastrointest Oncol. 2017 Sep 15;9(9):354-362. doi: 10.4251/wjgo.v9.i9.354.

4.

Utility of Appendiceal Calcifications Detected on Computed Tomography as a Predictor for an Underlying Appendiceal Epithelial Neoplasm.

Sagebiel TL, Mohamed A, Matamoros A, Taggart MW, Doamekpor F, Raghav KP, Mann GN, Mansfield PF, Eng C, Royal RE, Foo WC, Ensor JE, Fournier KF, Overman MJ.

Ann Surg Oncol. 2017 Nov;24(12):3667-3672. doi: 10.1245/s10434-017-6052-7. Epub 2017 Aug 22.

PMID:
28831698
5.

Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Moderately and Poorly Differentiated Appendiceal Adenocarcinoma: Survival Outcomes and Patient Selection.

Grotz TE, Overman MJ, Eng C, Raghav KP, Royal RE, Mansfield PF, Mann GN, Robinson KA, Beaty KA, Rafeeq S, Matamoros A, Taggart MW, Fournier KF.

Ann Surg Oncol. 2017 Sep;24(9):2646-2654. doi: 10.1245/s10434-017-5938-8. Epub 2017 Jul 10.

PMID:
28695394
6.

Retrospective study of nonmucinous appendiceal adenocarcinomas: role of systemic chemotherapy and cytoreductive surgery.

Uemura M, Qiao W, Fournier K, Morris J, Mansfield P, Eng C, Royal RE, Wolff RA, Raghav K, Mann GN, Overman MJ.

BMC Cancer. 2017 May 15;17(1):331. doi: 10.1186/s12885-017-3327-0.

7.

Intrathoracic Chemoperfusion Decreases Recurrences in Patients with Full-Thickness Diaphragm Involvement with Mucinous Appendiceal Adenocarcinoma.

Grotz TE, Mansfield PF, Royal RE, Mann GN, Rafeeq S, Beaty KA, Overman MJ, Fournier KF.

Ann Surg Oncol. 2016 Sep;23(9):2914-9. doi: 10.1245/s10434-016-5209-0. Epub 2016 Mar 30.

PMID:
27027310
8.

Association of Vitamin D Levels With Outcome in Patients With Melanoma After Adjustment For C-Reactive Protein.

Fang S, Sui D, Wang Y, Liu H, Chiang YJ, Ross MI, Gershenwald JE, Cormier JN, Royal RE, Lucci A, Wargo J, Hu MI, Gardner JM, Reveille JD, Bassett RL, Wei Q, Amos CI, Lee JE.

J Clin Oncol. 2016 May 20;34(15):1741-7. doi: 10.1200/JCO.2015.64.1357. Epub 2016 Mar 21.

9.

Results of a Randomized Controlled Multicenter Phase III Trial of Percutaneous Hepatic Perfusion Compared with Best Available Care for Patients with Melanoma Liver Metastases.

Hughes MS, Zager J, Faries M, Alexander HR, Royal RE, Wood B, Choi J, McCluskey K, Whitman E, Agarwala S, Siskin G, Nutting C, Toomey MA, Webb C, Beresnev T, Pingpank JF.

Ann Surg Oncol. 2016 Apr;23(4):1309-19. doi: 10.1245/s10434-015-4968-3. Epub 2015 Nov 23.

PMID:
26597368
10.

Feeding tube placement during cytoreductive surgery and heated intraperitoneal chemotherapy does not improve postoperative nutrition and is associated with longer length of stay and higher readmission rates.

Dineen SP, Robinson KA, Roland CL, Beaty KA, Rafeeq S, Mansfield PF, Royal RE, Fournier KF.

J Surg Res. 2016 Jan;200(1):158-63. doi: 10.1016/j.jss.2015.08.003. Epub 2015 Aug 13.

PMID:
26342838
11.

Association of Common Genetic Polymorphisms with Melanoma Patient IL-12p40 Blood Levels, Risk, and Outcomes.

Fang S, Wang Y, Chun YS, Liu H, Ross MI, Gershenwald JE, Cormier JN, Royal RE, Lucci A, Schacherer CW, Reveille JD, Chen W, Sui D, Bassett RL, Wang LE, Wei Q, Amos CI, Lee JE.

J Invest Dermatol. 2015 Sep;135(9):2266-2272. doi: 10.1038/jid.2015.138. Epub 2015 Apr 7.

12.

Is surviving enough? Coping and impact on activities of daily living among melanoma patients with lymphoedema.

Cromwell KD, Chiang YJ, Armer J, Heppner PP, Mungovan K, Ross MI, Gershenwald JE, Lee JE, Royal RE, Lucci A, Cormier JN.

Eur J Cancer Care (Engl). 2015 Sep;24(5):724-33. doi: 10.1111/ecc.12311. Epub 2015 Mar 24.

13.

C-reactive protein as a marker of melanoma progression.

Fang S, Wang Y, Sui D, Liu H, Ross MI, Gershenwald JE, Cormier JN, Royal RE, Lucci A, Schacherer CW, Gardner JM, Reveille JD, Bassett RL, Wang LE, Wei Q, Amos CI, Lee JE.

J Clin Oncol. 2015 Apr 20;33(12):1389-96. doi: 10.1200/JCO.2014.58.0209. Epub 2015 Mar 16.

14.

A Simplified Preoperative Assessment Predicts Complete Cytoreduction and Outcomes in Patients with Low-Grade Mucinous Adenocarcinoma of the Appendix.

Dineen SP, Royal RE, Hughes MS, Sagebiel T, Bhosale P, Overman M, Matamoros A, Mansfield PF, Fournier KF.

Ann Surg Oncol. 2015 Oct;22(11):3640-6. doi: 10.1245/s10434-015-4446-y. Epub 2015 Feb 20.

15.

Improved Survival with Anti-VEGF Therapy in the Treatment of Unresectable Appendiceal Epithelial Neoplasms.

Choe JH, Overman MJ, Fournier KF, Royal RE, Ohinata A, Rafeeq S, Beaty K, Phillips JK, Wolff RA, Mansfield PF, Eng C.

Ann Surg Oncol. 2015 Aug;22(8):2578-84. doi: 10.1245/s10434-014-4335-9. Epub 2015 Jan 13.

PMID:
25582740
16.

The relationship between blood IL-12p40 level and melanoma progression.

Fang S, Wang Y, Chun YS, Liu H, Ross MI, Gershenwald JE, Cormier JN, Royal RE, Lucci A, Schacherer CW, Reveille JD, Sui D, Bassett RL Jr, Wang LE, Wei Q, Amos CI, Lee JE.

Int J Cancer. 2015 Apr 15;136(8):1874-80. doi: 10.1002/ijc.29182. Epub 2014 Sep 18.

17.

Is surveillance imaging effective for detecting surgically treatable recurrences in patients with melanoma? A comparative analysis of stage-specific surveillance strategies.

Rueth NM, Xing Y, Chiang YJ, Cromwell KD, Ross MI, Lee JE, Gershenwald JE, Royal RE, Cormier JN.

Ann Surg. 2014 Jun;259(6):1215-22. doi: 10.1097/SLA.0000000000000233.

PMID:
24096759
18.

Prospective assessment of lymphedema incidence and lymphedema-associated symptoms following lymph node surgery for melanoma.

Hyngstrom JR, Chiang YJ, Cromwell KD, Ross MI, Xing Y, Mungovan KS, Lee JE, Gershenwald JE, Royal RE, Lucci A, Armer JM, Cormier JN.

Melanoma Res. 2013 Aug;23(4):290-7. doi: 10.1097/CMR.0b013e3283632c83.

19.

High-level microsatellite instability in appendiceal carcinomas.

Taggart MW, Galbincea J, Mansfield PF, Fournier KF, Royal RE, Overman MJ, Rashid A, Abraham SC.

Am J Surg Pathol. 2013 Aug;37(8):1192-200. doi: 10.1097/PAS.0b013e318282649b.

20.

Phase 1 prospective evaluation of the oncological adequacy of robotic assisted video-endoscopic inguinal lymphadenectomy in patients with penile carcinoma.

Matin SF, Cormier JN, Ward JF, Pisters LL, Wood CG, Dinney CP, Royal RE, Huang X, Pettaway CA.

BJU Int. 2013 Jun;111(7):1068-74. doi: 10.1111/j.1464-410X.2012.11729.x. Epub 2013 Apr 2.

21.

A novel nomogram for peritoneal mesothelioma predicts survival.

Schaub NP, Alimchandani M, Quezado M, Kalina P, Eberhardt JS, Hughes MS, Beresnev T, Hassan R, Bartlett DL, Libutti SK, Pingpank JF, Royal RE, Kammula US, Pandalai P, Phan GQ, Stojadinovic A, Rudloff U, Alexander HR, Avital I.

Ann Surg Oncol. 2013 Feb;20(2):555-61. doi: 10.1245/s10434-012-2651-5. Epub 2012 Dec 12.

22.

Pathologic complete response in poorly differentiated adenocarcinomas of the appendix: a case series.

Bilen MA, Taggart MW, Fournier K, Ellis LM, Mansfield PF, Eng C, Royal RE, Overman MJ.

Acta Oncol. 2013 Jun;52(5):1044-6. doi: 10.3109/0284186X.2012.724772. Epub 2012 Oct 1. No abstract available.

PMID:
23020527
23.

Variability in melanoma post-treatment surveillance practices by country and physician specialty: a systematic review.

Cromwell KD, Ross MI, Xing Y, Gershenwald JE, Royal RE, Lucci A, Lee JE, Cormier JN.

Melanoma Res. 2012 Oct;22(5):376-85. doi: 10.1097/CMR.0b013e328357d796. Review.

24.

A pilot feasibility study of TNFeradeā„¢ biologic with capecitabine and radiation therapy followed by surgical resection for the treatment of rectal cancer.

Citrin D, Camphausen K, Wood BJ, Quezado M, Denobile J, Pingpank JF, Royal RE, Alexander HR, Seidel G, Steinberg SM, Shuttack Y, Libutti SK.

Oncology. 2010;79(5-6):382-8. doi: 10.1159/000323488. Epub 2011 Mar 25.

25.

Liver resection and ablation for metastatic adrenocortical carcinoma.

Ripley RT, Kemp CD, Davis JL, Langan RC, Royal RE, Libutti SK, Steinberg SM, Wood BJ, Kammula US, Fojo T, Avital I.

Ann Surg Oncol. 2011 Jul;18(7):1972-9. doi: 10.1245/s10434-011-1564-z. Epub 2011 Feb 8.

26.

Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma.

Royal RE, Levy C, Turner K, Mathur A, Hughes M, Kammula US, Sherry RM, Topalian SL, Yang JC, Lowy I, Rosenberg SA.

J Immunother. 2010 Oct;33(8):828-33. doi: 10.1097/CJI.0b013e3181eec14c.

PMID:
20842054
27.

Identification and characterization of a tumor infiltrating CD56(+)/CD16 (-) NK cell subset with specificity for pancreatic and prostate cancer cell lines.

Frankel TL, Burns W, Riley J, Morgan RA, Davis JL, Hanada K, Quezado M, Rosenberg SA, Royal RE.

Cancer Immunol Immunother. 2010 Dec;59(12):1757-69. doi: 10.1007/s00262-010-0897-y. Epub 2010 Aug 24.

28.

Liver resection for metastatic melanoma with postoperative tumor-infiltrating lymphocyte therapy.

Ripley RT, Davis JL, Klapper JA, Mathur A, Kammula U, Royal RE, Yang JC, Sherry RM, Hughes MS, Libutti SK, White DE, Steinberg SM, Dudley ME, Rosenberg SA, Avital I.

Ann Surg Oncol. 2010 Jan;17(1):163-70. doi: 10.1245/s10434-009-0677-0. Epub 2009 Sep 24.

29.

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen.

Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS, Kammula US, Royal RE, Sherry RM, Wunderlich JR, Lee CC, Restifo NP, Schwarz SL, Cogdill AP, Bishop RJ, Kim H, Brewer CC, Rudy SF, VanWaes C, Davis JL, Mathur A, Ripley RT, Nathan DA, Laurencot CM, Rosenberg SA.

Blood. 2009 Jul 16;114(3):535-46. doi: 10.1182/blood-2009-03-211714. Epub 2009 May 18.

30.

Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines.

Smith FO, Downey SG, Klapper JA, Yang JC, Sherry RM, Royal RE, Kammula US, Hughes MS, Restifo NP, Levy CL, White DE, Steinberg SM, Rosenberg SA.

Clin Cancer Res. 2008 Sep 1;14(17):5610-8. doi: 10.1158/1078-0432.CCR-08-0116.

31.

High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma : a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006.

Klapper JA, Downey SG, Smith FO, Yang JC, Hughes MS, Kammula US, Sherry RM, Royal RE, Steinberg SM, Rosenberg S.

Cancer. 2008 Jul 15;113(2):293-301. doi: 10.1002/cncr.23552.

32.

Diagnosis and management of peritoneal carcinomatosis arising from adenocarcinoma of the colon and rectum.

Royal RE, Pingpank JF Jr.

Semin Oncol. 2008 Apr;35(2):183-91. doi: 10.1053/j.seminoncol.2007.12.007. Review.

PMID:
18396204
33.

Combining agents that target the tumor microenvironment improves the efficacy of anticancer therapy.

Blansfield JA, Caragacianu D, Alexander HR 3rd, Tangrea MA, Morita SY, Lorang D, Schafer P, Muller G, Stirling D, Royal RE, Libutti SK.

Clin Cancer Res. 2008 Jan 1;14(1):270-80. doi: 10.1158/1078-0432.CCR-07-1562.

34.

Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade.

Downey SG, Klapper JA, Smith FO, Yang JC, Sherry RM, Royal RE, Kammula US, Hughes MS, Allen TE, Levy CL, Yellin M, Nichol G, White DE, Steinberg SM, Rosenberg SA.

Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6681-8. Epub 2007 Nov 2.

35.

Interleukin-4 cytotoxin therapy synergizes with gemcitabine in a mouse model of pancreatic ductal adenocarcinoma.

Shimamura T, Royal RE, Kioi M, Nakajima A, Husain SR, Puri RK.

Cancer Res. 2007 Oct 15;67(20):9903-12.

36.

Determination of the elimination half-life of fibroblast growth factor-23.

Khosravi A, Cutler CM, Kelly MH, Chang R, Royal RE, Sherry RM, Wodajo FM, Fedarko NS, Collins MT.

J Clin Endocrinol Metab. 2007 Jun;92(6):2374-7. Epub 2007 Mar 20.

PMID:
17374707
37.

Cancer regression in patients after transfer of genetically engineered lymphocytes.

Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, Royal RE, Topalian SL, Kammula US, Restifo NP, Zheng Z, Nahvi A, de Vries CR, Rogers-Freezer LJ, Mavroukakis SA, Rosenberg SA.

Science. 2006 Oct 6;314(5796):126-9. Epub 2006 Aug 31.

38.

Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma.

Maker AV, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Hughes M, Yellin MJ, Haworth LR, Levy C, Allen T, Mavroukakis SA, Attia P, Rosenberg SA.

J Immunother. 2006 Jul-Aug;29(4):455-63.

39.

Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4.

Beck KE, Blansfield JA, Tran KQ, Feldman AL, Hughes MS, Royal RE, Kammula US, Topalian SL, Sherry RM, Kleiner D, Quezado M, Lowy I, Yellin M, Rosenberg SA, Yang JC.

J Clin Oncol. 2006 May 20;24(15):2283-9.

40.

Altered CD8(+) T-cell responses when immunizing with multiepitope peptide vaccines.

Rosenberg SA, Sherry RM, Morton KE, Yang JC, Topalian SL, Royal RE, Kammula US, Restifo NP, Hughes MS, Schwarz SL, Ngo LT, Mavroukakis SA, White DE.

J Immunother. 2006 Mar-Apr;29(2):224-31.

41.

Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study.

Maker AV, Phan GQ, Attia P, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Haworth LR, Levy C, Kleiner D, Mavroukakis SA, Yellin M, Rosenberg SA.

Ann Surg Oncol. 2005 Dec;12(12):1005-16. Epub 2005 Oct 21.

42.

Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma.

Rosenberg SA, Sherry RM, Morton KE, Scharfman WJ, Yang JC, Topalian SL, Royal RE, Kammula U, Restifo NP, Hughes MS, Schwartzentruber D, Berman DM, Schwarz SL, Ngo LT, Mavroukakis SA, White DE, Steinberg SM.

J Immunol. 2005 Nov 1;175(9):6169-76.

43.

Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer.

Blansfield JA, Beck KE, Tran K, Yang JC, Hughes MS, Kammula US, Royal RE, Topalian SL, Haworth LR, Levy C, Rosenberg SA, Sherry RM.

J Immunother. 2005 Nov-Dec;28(6):593-8.

44.

Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.

Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Restifo NP, Haworth LR, Levy C, Mavroukakis SA, Nichol G, Yellin MJ, Rosenberg SA.

J Clin Oncol. 2005 Sep 1;23(25):6043-53. Epub 2005 Aug 8.

45.

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.

Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, Royal RE, Kammula U, White DE, Mavroukakis SA, Rogers LJ, Gracia GJ, Jones SA, Mangiameli DP, Pelletier MM, Gea-Banacloche J, Robinson MR, Berman DM, Filie AC, Abati A, Rosenberg SA.

J Clin Oncol. 2005 Apr 1;23(10):2346-57.

46.

Improving the yield of preoperative parathyroid localization: technetium Tc 99m-sestamibi imaging after thyroid suppression.

Royal RE, Delpassand ES, Shapiro SE, Fritsche HA Jr, Vassilopoulou-Sellin R, Sherman SI, Gagel RF, Evans DB, Lee JE.

Surgery. 2002 Dec;132(6):968-74; discussion 974-5.

PMID:
12490843
47.

Increased functional expression of transgene in primary human lymphocytes using retroviral vectors modified with IRES and splicing motifs.

Royal RE, Kershaw MH, Reeves ME, Wang G, Daly T, Treisman J, Lam J, Hwu P.

Gene Ther. 2002 Aug;9(16):1085-92.

48.

Advanced proximal colon cancer.

Gannon CJ, Malone DL, Royal RE, Schreiber M, Bass BL, Napolitano LM.

Surg Endosc. 2002 Mar;16(3):446-9. Epub 2001 Nov 16.

PMID:
11928025
49.
50.

Recognition of human colon cancer by T cells transduced with a chimeric receptor gene.

Daly T, Royal RE, Kershaw MH, Treisman J, Wang G, Li W, Herlyn D, Eshhar Z, Hwu P.

Cancer Gene Ther. 2000 Feb;7(2):284-91.

Supplemental Content

Loading ...
Support Center